A medium-sized RCT from the Imperial College. The research question are of interest for all cardiovascular, thoracic, and general surgeons as well as all healthcare professionals.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Heart Failure - Nonischemic
May 11, 2020
Interesting hypothesis in a rodent model of myxomatous degeneration.
January 30, 2020
The American Association for Thoracic Surgery and International Society for Heart and Lung Transplantation provide a consensus guidelines document on ten important aspects in mechanical circulatory support. These include:
December 4, 2019
Well-presented Canadian prospective study juxtaposing a combination of Wells scoring and dimers to the imaging gold standard.
It was particularly fascinating to read the referenced assertion that:
October 14, 2019
A narrative review offering an intensivists' viewpoint on specific cardiovascular sequela of double-lumen anaesthesia for pulmonary resections (and by extension, implantation of donor lungs) and other cardiothoracic and vascular operations.
September 5, 2019
The January update of an expert panel from the American College of Chest Physicians on the expanding clinical entity of pulmonary hypertension, especially pertinent to the transplant community.
August 13, 2019
The translational value for cardiac transplantation of this prospective multi-centre clinical study of vasodilation in amyloidosis remains to be evaluated.
March 26, 2019
The investigators published the final analysis of the MOMENTUM 3 trial comparing the fully magnetically levitated centrifugal continuous-flow HeartMate 3 pump to the mechanical-bearing axial continuous-flow HeartMate II pump.
February 7, 2019
In the February issue of The Annals, The Society of Thoracic Surgeons published the first annual report after the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) joined the STS National Database in January 2018. This report summarizes the outcomes in patients (≥19 years of age) undergoing durable MCS implant b
February 5, 2019
In a letter to healthcare providers, the US FDA summarized a recent evaluation of a postapproval study of the Abiomed Impella RP system. In clinical trials, 73% of patients survived 30 days after device explant, hospital discharge, or to definitive intervention. In the postapproval study, just over 17% of patients met this goal.